Valuation: Rhelion Life Sciences Corp.

Market Cap 12.28M 8.69M 7.76M 7.14M 6.48M 815M 12.59M 85.42M 34.05M 436M 32.63M 31.93M 1.37B P/E 2025
-2.98x
P/E 2026 -1.71x
Enterprise Value 4.05M 2.87M 2.56M 2.35M 2.14M 269M 4.15M 28.17M 11.23M 144M 10.76M 10.53M 453M EV / Sales 2025
0.29x
EV / Sales 2026 0.57x
Free-Float
94.46%
Yield 2025 *
-
Yield 2026 -
1 month-20.00%
3 months-33.33%
6 months-55.56%
1 week 0.02
Extreme 0.015
0.02
1 month 0.02
Extreme 0.015
0.03
Current year 0.02
Extreme 0.015
0.05
1 year 0.02
Extreme 0.015
0.05
3 years 0.02
Extreme 0.015
0.08
5 years 0.02
Extreme 0.015
0.19
10 years 0.02
Extreme 0.015
0.7
Manager TitleAgeSince
Chief Executive Officer - 2020-05-21
Director of Finance/CFO - 2026-08-18
President 40 -
Director TitleAgeSince
Chairman - 1982-09-28
Chairman - 2020-05-24
Director/Board Member 31 2019-02-28
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-33.33%-63.64% 8.69M
+3.41%-1.49%+13.06%+62.95% 48.4B
+0.34%+7.53%-10.38%+19.69% 37.53B
+0.89%+6.39%-5.35%-7.92% 16.92B
-0.71%+2.68%-15.22%+8.74% 12.06B
+0.56%+5.01%-27.32%-29.34% 5.3B
+0.50%+2.54%-2.42%+7.45% 4.93B
+0.69%+2.84%-3.01%+5.07% 4B
+3.87%-9.94%-25.49%+272.91% 3.98B
-1.68%-1.32%-7.98%+7.83% 3.6B
Average +0.79%+0.34%-11.74%+28.38% 14B
Weighted average by Cap. +1.48%+0.77%-2.42%+34.91%

Financials

2025 2026
Net sales 4.94M 3.5M 3.12M 2.87M 2.61M 328M 5.07M 34.39M 13.71M 176M 13.14M 12.86M 553M 4.2M 2.97M 2.65M 2.44M 2.21M 278M 4.3M 29.18M 11.63M 149M 11.15M 10.91M 469M
Net income -4.04M -2.86M -2.55M -2.35M -2.13M -268M -4.14M -28.11M -11.21M -144M -10.74M -10.51M -452M -6.1M -4.32M -3.86M -3.55M -3.22M -405M -6.25M -42.44M -16.92M -217M -16.21M -15.87M -683M
Net Debt -10.87M -7.69M -6.87M -6.32M -5.73M -721M -11.14M -75.59M -30.13M -386M -28.88M -28.26M -1.22B -8.23M -5.83M -5.2M -4.79M -4.34M -546M -8.44M -57.26M -22.82M -292M -21.87M -21.4M -921M
Projected Income Statement - Annual - Rhelion Life Sciences Corp.
Logo Rhelion Life Sciences Corp.
Rhelion Life Sciences Corp., formerly Red Light Holland Corp., is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health Corp., the Company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with institutions around the world. PEX010 is its standardized natural psilocybin drug candidate, studied across 80+ clinical trials worldwide, including FDA-authorized programs in depression, PTSD, cancer-related distress, and substance use disorders. Its products also include IBEXX and MB2500. IBEXX is its botanical ibogaine drug candidate. MB2500 is its whole-leaf coca extract drug candidate. It also operates in the Netherlands' legal adult-use market and supports voluntary data collection and research to help advance the scientific understanding of natural psychedelics.
Employees
-
Date Price Change Volume
26-11-09 $0.0200 0.00% 37,350
26-11-06 $0.0200 0.00% 105,192
26-11-05 $0.0200 0.00% 305,748
26-11-04 $0.0200 0.00% 121,006
26-11-03 $0.0200 0.00% 198,780
  1. Stock Market
  2. Stocks
  3. RHEL Stock